Amolyt Pharma today presented positive data from the first cohorts of the single ascending dose portion of its Phase 1 clinical trial in healthy volunteers evaluating the company’s lead clinical candidate, AZP- 3601, for the treatment of hypoparathyroidism. The data demonstrated a significant, sustained increase in blood calcium levels for at least 24 hours following a single administration of AZP- 3601. The data were presented as a virtual poster at the Endocrine Society’s Annual Meeting (ENDO 2021).

Complete press release Amolyt Pharma